Assessing Ocugen (OCGN) Valuation After Positive OCU410 Gene Therapy Data And Equity Raise

Simply Wall St.01-24 18:21

Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605239035?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-24 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605239035","market":"us","top_or_hot":-1,"title":"Assessing Ocugen (OCGN) Valuation After Positive OCU410 Gene Therapy Data And Equity Raise","media":"Simply Wall St.","content":"<div>\n<p>Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-positive-ocu410-gene-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ocugen (OCGN) Valuation After Positive OCU410 Gene Therapy Data And Equity Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ocugen (OCGN) Valuation After Positive OCU410 Gene Therapy Data And Equity Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-24 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-positive-ocu410-gene-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-positive-ocu410-gene-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQR","symbol_name":"资产住宅公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-positive-ocu410-gene-t","article_id":"2605239035","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-positive-ocu410-gene-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605239035","pubTimestamp":1769250087,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 per share.\nSee our latest analysis for Ocugen.\nOcugen’s latest OCU410 trial update and the US$22.5 million equity raise come after a period where the stock has seen a 20.29% year to date share price return and a very large 112.82% one year total shareholder return. This suggests recent news is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQR":"资产住宅公司","BK4215":"住宅房地产投资信托","BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","OCGN":"Ocugen","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"在OCU410基因治疗数据积极和股权融资后评估Ocugen(OCGN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"OCGN":1.5},"content_text":"Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 per share. See our latest analysis for Ocugen. Ocugen’s latest OCU410 trial update and the US$22.5 million equity raise come after a period where the stock has seen a 20.29% year to date share price return and a very large 112.82% one year total shareholder return. This suggests recent news is feeding into stronger momentum and shifting views on its risk and growth profile. If Ocugen’s gene therapy progress has caught your attention, this could be a good moment to see what else is happening across healthcare stocks for more potential ideas in the sector. With the share price already up strongly over the past year, a recent follow on raise at US$1.50 and a last close of US$1.66, you have to ask: is Ocugen still mispriced, or is the market already baking in future growth? AdvertisementMost Popular Narrative: 81.6% Undervalued Ocugen’s most followed valuation story pegs fair value at US$9.00 versus a last close of US$1.66, so the gap between price and expectations is wide.  Ocugen is progressing multiple gene therapy candidates (OCU400, OCU410, OCU410ST) towards late-stage trials and regulatory filings, with three market authorization applications planned in the next three years. These therapies address large global patient populations with significant unmet needs, increasing the potential for substantial future revenue growth.  Read the complete narrative. Curious what kind of revenue ramp, margin profile, and future earnings multiple sit behind that US$9.00 figure and very large discount rate input? The full narrative breaks down how these moving parts fit together and what needs to happen for Ocugen to grow into that valuation. Result: Fair Value of $9 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story still hinges on unapproved therapies and a significant cash burn, so any trial setback or funding squeeze could quickly challenge that US$9.00 narrative. Find out about the key risks to this Ocugen narrative. Another View: Multiples Flash A Very Different Signal That US$9.00 fair value is built on forward-looking cash flow work, but Ocugen’s current P/B of 154.1x versus 2.7x for the US Biotechs industry and 1.5x for peers points the other way. At this kind of gap, is the real risk that expectations are already stretched? See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:OCGN P/B Ratio as at Jan 2026 Build Your Own Ocugen Narrative If you look at the numbers and reach a different conclusion, or simply prefer testing your own assumptions, you can build a personalized Ocugen view in just a few minutes with Do it your way. A great starting point for your Ocugen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If Ocugen is on your watchlist, do not stop there; the right screener can surface other opportunities that fit the way you like to invest.  Spot potential value candidates early by scanning these 864 undervalued stocks based on cash flows that align with your return expectations and risk comfort. Chase next generation growth stories by tracking these 24 AI penny stocks where artificial intelligence is central to the business model. Tap into powerful income themes by reviewing these 13 dividend stocks with yields > 3% that might complement a long term total return approach.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605239035","isCrawlerRequest":true}